Infectious Diseases
Meningitis Empiric Antibiotic Selection
Choose empiric therapy by acquisition setting, age, immune status, and neurosurgical hardware exposure; obtain blood cultures and CSF promptly, but do not delay antibiotics for imaging or lumbar puncture when either will defer treatment.
Immediate action
Start antibiotics after blood cultures; do not wait for lumbar puncture
Acquisition setting determines the initial regimen.
In suspected bacterial meningitis, draw blood cultures immediately and perform lumbar puncture for CSF microscopy, Gram stain, culture, and pathogen testing when feasible; initiate empiric treatment before CSF results return. ScienceDirect+1ScienceDirectBacterial Meningitis - an overviewCDCMeningococcal Disease | CDC Yellow Book™ If neuroimaging or another barrier delays lumbar puncture, obtain blood cultures and give broad, age- and risk-appropriate antimicrobials rather than defer treatment. ScienceDirectScienceDirectEpidemic Meningitis - an overview | ScienceDirect Topics
For suspected community-acquired disease in immunocompetent adults age 50 years or younger, start vancomycin plus either ceftriaxone 2 g IV every 12 hours or cefotaxime 2 g IV every 4 hours. This combination covers the predominant adult pathogens, Streptococcus pneumoniae and Neisseria meningitidis, while addressing concern for cephalosporin-nonsusceptible pneumococci. PubMed+1PubMedEpidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis - PMCccjm[PDF] Acute community-acquired bacterial meningitis in adults
Use meningitis, rather than routine infection, doses for drugs with limited CSF penetration; ceftriaxone for pneumococcal meningitis is dosed at 2 g IV every 12 hours. ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults
Tailor therapy promptly to CSF Gram stain, culture, and susceptibility results. ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults
| Clinical setting | Initial regimen | Selection rationale |
|---|---|---|
| Community-acquired; immunocompetent adult age 50 years or younger | Vancomycin plus ceftriaxone 2 g IV every 12 hours or cefotaxime 2 g IV every 4 hours ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults | Covers common adult pneumococcal and meningococcal disease and resistant pneumococci. PubMed+1PubMedEpidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis - PMCccjm[PDF] Acute community-acquired bacterial meningitis in adults |
| Community-acquired; age over 50 years or cell-mediated immunodeficiency | Vancomycin plus ceftriaxone or cefotaxime, plus ampicillin 2 g IV every 4 hours ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults | Add ampicillin for L. monocytogenes coverage. ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults |
| Healthcare-associated ventriculitis or meningitis | Vancomycin plus cefepime, ceftazidime, or meropenem IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis | Select the antipseudomonal beta-lactam according to local in vitro susceptibility patterns. IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis |
| Severe beta-lactam anaphylaxis with healthcare-associated disease and meropenem contraindicated | Vancomycin plus aztreonam or ciprofloxacin for gram-negative coverage IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis | IDSA alternative when beta-lactams cannot be used. IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis |
Community acquired
Add ampicillin when Listeria risk changes the regimen
Age and cellular immune status are the practical discriminators.
Add ampicillin 2 g IV every 4 hours to vancomycin plus ceftriaxone or cefotaxime for patients older than 50 years and for those with cell-mediated immunodeficiency. ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults Do not rely on a third-generation cephalosporin alone when Listeria is a credible pathogen, because the treatment branch specifically requires ampicillin coverage. ScienceDirect+1ScienceDirectBacterial Meningitis - an overviewccjm[PDF] Acute community-acquired bacterial meningitis in adults
Vancomycin is included empirically because pneumococcal resistance can compromise beta-lactam-only therapy. PubMed+1PubMedEpidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis - PMCccjm[PDF] Acute community-acquired bacterial meningitis in adults A cited adult regimen uses vancomycin 45-60 mg/kg/day IV divided every 6 or 8 hours to improve CSF concentrations. ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults Once an organism and susceptibility profile are available, narrow the regimen rather than continuing broad combination therapy by default. ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults
If pneumococcal cefotaxime or ceftriaxone MIC is 0.5 micrograms/mL or less, cefotaxime or ceftriaxone is probably adequate; if MIC is 1 microgram/mL or more, vancomycin is identified as the treatment of choice in the cited review. ScienceDirectScienceDirectBacterial Meningitis - an overview
Some experts add rifampin to vancomycin plus an expanded-spectrum cephalosporin when a pneumococcal isolate is likely highly resistant based on local resistance patterns; clinical efficacy data for this addition are lacking. PubMedPubMedEpidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis - PMC
| Result or clinical determination | Action |
|---|---|
| N. meningitidis confirmed or suspected | Continue a third-generation cephalosporin initially; obtain isolate susceptibility before changing to penicillin or ampicillin. CDCCDCMeningococcal Disease | CDC Yellow Book™ |
| Pneumococcal cefotaxime or ceftriaxone MIC 0.5 micrograms/mL or less | Cefotaxime or ceftriaxone is probably adequate. ScienceDirectScienceDirectBacterial Meningitis - an overview |
| Pneumococcal cefotaxime or ceftriaxone MIC 1 microgram/mL or more | Use vancomycin as the treatment of choice described in the cited review. ScienceDirectScienceDirectBacterial Meningitis - an overview |
| Culture and susceptibility available | Tailor antimicrobial therapy to the identified pathogen and susceptibility profile. ccjmccjm[PDF] Acute community-acquired bacterial meningitis in adults |
Postprocedural disease
Use antipseudomonal gram-negative coverage after neurosurgical exposure
Do not apply the community-acquired regimen to hardware-associated infection.
For healthcare-associated ventriculitis or meningitis, initiate vancomycin plus cefepime, ceftazidime, or meropenem. IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis This branch applies when the epidemiology is iatrogenic or postneurosurgical rather than community acquired, where gram-negative pathogens including Pseudomonas must be covered empirically. ScienceDirect+1ScienceDirectBacterial Meningitis - an overviewIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis
Choose cefepime, ceftazidime, or meropenem using local in vitro susceptibility data, and broaden or modify empiric coverage when the patient is colonized or infected elsewhere with a highly antimicrobial-resistant pathogen. IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis In seriously ill adults receiving intermittent-bolus vancomycin, maintain a trough concentration of 15-20 micrograms/mL. IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis
For beta-lactam anaphylaxis when meropenem is contraindicated, use aztreonam or ciprofloxacin for gram-negative coverage alongside vancomycin. IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis
Obtain microbiologic confirmation and revise therapy to organism-directed treatment when culture and susceptibility data become available. IDSAIDSAIDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis
Microbiologic direction
Use CSF Gram stain, culture, and PCR to narrow therapy
Negative culture after prior antibiotics does not exclude bacterial meningitis.
Send CSF for microscopic examination, Gram stain, and culture, with pathogen-specific PCR when meningococcal disease is suspected. N. meningitidis may be confirmed by culture or PCR from a normally sterile site such as blood or CSF; Gram stain provides rapid presumptive identification but is not confirmatory. CDC+1CDCMeningococcal Disease | CDC Yellow Book™CDCMeningococcal Disease | Infection Control - CDC
Prior antibacterial therapy can reduce culture yield. In a 451-specimen study of pneumococcal, meningococcal, and H. influenzae meningitis, culture was positive in 17.7% and real-time PCR in 25.1%; latent-class sensitivity estimates were 81.3% for culture, 98.2% for Gram stain, and 95.7% for real-time PCR. CDCCDC[PDF] Accuracy of real-time PCR, Gram stain and culture for ... - CDC Stacks Therefore, retain clinically appropriate empiric treatment while interpreting negative cultures in patients who received antibiotics before CSF collection. CDCCDC[PDF] Accuracy of real-time PCR, Gram stain and culture for ... - CDC Stacks
Consider broad-range 16S rRNA PCR with sequencing for selected complex infections involving normally sterile fluids or tissues when conventional testing fails to identify a pathogen; it can detect fastidious bacteria and may support antimicrobial stewardship, although diagnostic yield varies by specimen and patient characteristics. CDCCDC16S Ribosomal RNA Gene PCR and Sequencing for Pediatric Infection Diagnosis, United States, 2020–2023 - Volume 31, Supplement—May 2025 - Emerging Infectious Diseases journal - CDC
Report meningococcal disease promptly to state or local public health authorities. CDCCDCMeningococcal Disease | CDC Yellow Book™
For confirmed or probable meningococcal disease, arrange close-contact chemoprophylaxis as soon as possible, ideally within 24 hours after identification of the index patient; prophylaxis given more than 14 days after illness onset is likely of limited or no value. CDCCDCMeningococcal Disease | Infection Control - CDC
Meningococcal disease
Separate index-patient treatment from contact prophylaxis
Organism confirmation triggers immediate public health action.
For the index patient with suspected meningococcal meningitis, a third-generation cephalosporin is recommended empirically. CDCCDCMeningococcal Disease | CDC Yellow Book™ If dexamethasone was started for suspected bacterial meningitis, it can be discontinued when meningococcal meningitis is confirmed or suspected. CDCCDCMeningococcal Disease | CDC Yellow Book™
For close contacts, rifampin, ciprofloxacin, and ceftriaxone are acceptable chemoprophylaxis agents and reduce nasopharyngeal meningococcal carriage by 90%-95%. CDCCDCMeningococcal Disease | Infection Control - CDC Treat eligible contacts promptly; microbiologically unconfirmed cases require case-by-case prophylaxis decisions based on the source patient's epidemiologic and clinical likelihood of meningococcal disease. CDCCDCMeningococcal Disease | Infection Control - CDC
| Decision point | Action |
|---|---|
| Suspected meningococcal meningitis | Use a third-generation cephalosporin empirically. CDCCDCMeningococcal Disease | CDC Yellow Book™ |
| Considering penicillin or ampicillin de-escalation | First determine meningococcal isolate susceptibility. CDCCDCMeningococcal Disease | CDC Yellow Book™ |
| Close contact identified | Provide chemoprophylaxis ideally within 24 hours of index-patient identification. CDCCDCMeningococcal Disease | Infection Control - CDC |
| More than 14 days after index illness onset | Chemoprophylaxis is probably of limited or no value. CDCCDCMeningococcal Disease | Infection Control - CDC |
References
- [PDF] 209445Orig1s000 - accessdata.fda.gov — www.accessdata.fda.gov · www.accessdata.fda.gov
- Empirical vancomycin therapy in childhood meningitis may not be necessary: Response to recent NICE guidelines | The BMJ — www.bmj.com · www.bmj.com
- Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance | The BMJ — www.bmj.com · www.bmj.com
- Opportunistic etiological agents causing lung infections - Cell Press — www.cell.com · www.cell.com
- Bacterial Meningitis - an overview — www.sciencedirect.com · www.sciencedirect.com
- Epidemic Meningitis - an overview | ScienceDirect Topics — www.sciencedirect.com · www.sciencedirect.com
- Update on community-acquired bacterial meningitis: guidance and ... — www.sciencedirect.com · www.sciencedirect.com
- Role of cephalosporins in the treatment of bacterial meningitis in adults: Overview with special emphasis on ceftazidime - ScienceDirect — www.sciencedirect.com · www.sciencedirect.com
- Efficacy of Antibiotic Regimens for Meningitis in Young Infants Aged ... — publications.aap.org · publications.aap.org
- Meningitis | Pediatric Care Online - AAP Publications — publications.aap.org · publications.aap.org
- [PDF] Accuracy of real-time PCR, Gram stain and culture for ... - CDC Stacks — stacks.cdc.gov · stacks.cdc.gov
- Meningococcal Disease | CDC Yellow Book™ — www.cdc.gov · www.cdc.gov
- Meningococcal Disease | Infection Control - CDC — www.cdc.gov · www.cdc.gov
- 16S Ribosomal RNA Gene PCR and Sequencing for Pediatric Infection Diagnosis, United States, 2020–2023 - Volume 31, Supplement—May 2025 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov · wwwnc.cdc.gov
- Diagnostic test accuracy of jolt accentuation for headache in acute ... — www.cochranelibrary.com · www.cochranelibrary.com
- [PDF] NG240 Meningitis (bacterial) and meningococcal disease - NICE — www.nice.org.uk · www.nice.org.uk
- [PDF] Meningitis (bacterial) and meningococcal disease - NICE — www.nice.org.uk · www.nice.org.uk
- [PDF] Meningitis (bacterial) and meningococcal disease: recognition ... — www.nice.org.uk · www.nice.org.uk
- IDSA 2017 Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis — www.idsociety.org · www.idsociety.org
- Skin and Soft Tissue Infections - IDSA — www.idsociety.org · www.idsociety.org
- Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis - PMC — www.ncbi.nlm.nih.gov · www.ncbi.nlm.nih.gov
- [PDF] Acute community-acquired bacterial meningitis in adults — www.ccjm.org · www.ccjm.org
- [PDF] Scientific advice under Article 107(6) of Regulation (EU) — www.ema.europa.eu · www.ema.europa.eu
- Adult bacterial meningitis: aetiology, penicillin susceptibility, risk ... — www.sciencedirect.com · www.sciencedirect.com